• Insulet launches campaign inspired by the International Diabetes Federation’s focus on diabetes, well-being, and the workplace
• “The Day Diabetes Showed Up to Work” campaign recognizes the unique needs of a person with diabetes in their professional life with a new global survey and resources
• Data shows that over 1 in 3 respondents feel the overall mental strain of managing diabetes has made their jobs more difficult

Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod^® brand of products, today announced its new campaign, “The Day Diabetes Showed Up to Work,” in honor of Diabetes Awareness Month, which starts November 1.

“Nearly 590 million people worldwide live with diabetes¹, and approximately 70 percent are of working age. Yet too often their experience at work is shaped by misunderstanding, fear of disclosure, and a lack of meaningful support,” said Ashley McEvoy, Insulet President and Chief Executive Officer. “At Insulet, we’re proud to shine a light on this important issue and spark action in the workplace that helps people with diabetes focus on what matters most – doing their best work and living their best lives.”

To better understand the impact of diabetes in the workplace, Insulet commissioned an external global survey² of 9,656 workers with type 1, type 2, and gestational diabetes, as well as caregivers and those without diabetes, across more than 10 sectors in 11 countries.

The survey revealed three key issues faced by people with diabetes (PWD) and their caregivers in their professional life:

Misunderstanding of Diabetes Underscores Need for Education and Broader Support

• 42% of PWD and caregivers surveyed reported experiencing workplace-related anxiety tied to diabetes management
• While 57% of respondents without diabetes say they feel confident³ supporting colleagues with the condition, 21% of PWD say poor awareness from colleagues makes their job more difficult
• 61% without diabetes cannot confidently identify the symptoms of type 1 diabetes, yet almost half are confident naming pop culture references like Harry Potter characters (41%) or their country’s top football teams (46%)

Despite Growing Awareness, Stigma Around Diabetes Remains Deeply Entrenched in Many Workplaces

• 79%⁴ of PWD have faced bias or misunderstanding at work
• Over one in four (27%) respondents reported fears that diabetes could limit opportunities that can be pursued or lead to discrimination and judgment in the workplace
• Nearly a quarter (21%) of PWDs conceal their condition from colleagues or managers

Creating a Workplace That Supports Diabetes Management Starts with Listening to What Employees Need and Acting on It

• 86%⁵ of PWD experience barriers at work due to their diabetes and employers have clear opportunities to improve inclusion
• Offering private spaces, a variety of food options, and adequate breaks can remove obstacles for the 57% of PWD who struggle with at least one of these barriers
• Mindfulness tools also show strong impact, with respondents reporting reduced stress, better sleep, and less anxiety. These are actionable steps that build resilience, reduce burnout, and foster a culture of care

“I wish more employers understood that diabetes may not be a visible chronic illness, but it affects many spheres of our lives, whether it’s in terms of our mental or physical health, or even our emotions,” said Judy Mitri, a communications professional and Omnipod user in Canada. “A little empathy can go a long way.”

This November, Insulet is launching a suite of resources to spark awareness and action around diabetes in the workplace. A dedicated campaign landing page will feature a whitepaper on healthcare provider support, an infographic with key survey insights, personal stories from Omnipod users and employees with diabetes, and practical checklists for supporting colleagues.

This campaign marks the beginning of a sustained effort by Insulet to elevate the conversation around diabetes and well-being. Insulet will continue to drive awareness, support, and inclusion throughout 2026 and beyond.

Additional Diabetes Awareness Month Activities and Events at Insulet

In celebration of Diabetes Awareness Month, Insulet is proud to support a range of meaningful initiatives that raise awareness, foster community, and give back to those impacted by diabetes.

• Charitable Donations: Through its Insulet for Good program, the Company will donate to the American Diabetes Association and the International Diabetes Federation to support workplace-focused programming for people with diabetes.
• Letters of Support for Children: Employees will write handwritten letters of encouragement to children recently diagnosed with type 1 diabetes, in collaboration with Breakthrough T1D.
• Community Event Sponsorships: Insulet will sponsor several community events throughout November, including initiatives by Risely Health, Children with Diabetes, Team Together, Fundación Phabian, and more.
• Employee Stories: Members of Insulet’s Podder^® Alliance Network, a group of employees living with, caring for, or supporting people with diabetes, are sharing their perspectives on managing diabetes in the workplace and how diabetes has impacted their professional career.

For more information on Diabetes Awareness and “The Day Diabetes Showed Up to Work,” please visit https://www.omnipod.com/diabetes-awareness.

About Insulet Corporation:

Insulet Corporation (NASDAQ: PODD), headquartered in Massachusetts, is an innovative medical device company dedicated to simplifying life for people with diabetes and other conditions through its Omnipod product platform. The Omnipod Insulin Management System provides a unique alternative to traditional insulin delivery methods. With its simple, wearable design, the tubeless disposable Pod provides up to three days of non-stop insulin delivery, without the need to see or handle a needle. Insulet’s flagship innovation, the Omnipod 5 Automated Insulin Delivery System, integrates with a continuous glucose monitor to manage blood sugar with no multiple daily injections, zero fingersticks, and can be controlled by a compatible personal smartphone in the U.S. or by the Omnipod 5 Controller. Insulet also leverages the unique design of its Pod by tailoring its Omnipod technology platform for the delivery of non-insulin subcutaneous drugs across other therapeutic areas. For more information, visit: insulet.com and omnipod.com.

©2025 Insulet Corporation. Omnipod and Podder are registered trademarks of Insulet Corporation. All rights reserved.

View source version on businesswire.com: https://www.businesswire.com/news/home/20251030324919/en/